KALA's Business Model
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.kalarx.com |
| CEO (Chief Executive Officer) | David Elliot Lazar |
| Number of Employees | |
| IPO date | July 20, 2017 |
KALA Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 1167 Massachusetts Avenue |
| City | Arlington |
| State | MA |
| Phone | 781 996 5252 |
| Zip Code | 02476 |
| Other Identifiers | |
| CIK | 0001479419 |
| ISIN | US4831192020 |
| CUSIP | 483119103 |
| Open | 0.365 |
| Previous Close | 0.3633 |
| Volume | 207.1 Thou. |
| Average Volume | 8.22 Mil. |
| Day’s Range | 0.3531 – 0.3902 |
| 52 Week Range | 0.3528-20.6 |
| MA (50) | 0.6173 |
| MA (200) | 4.39736 |
| Market Cap | 8.05 Mil. |
| Shares Out. | 21.93 Mil. |
| Earnings Date | Mar 26, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
